Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.68 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.68 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.68 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.68 |
| ▸ | ACE | P12821 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.68 |
| ▸ | FAP | Q12884 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14634817 | 1.00 | DPP4 (0.68) | DPP4DPP8DPP7DPP9ACE | |
| Phosphoric Acid SCHEMBL2570242 | 0.96 | DPP4 (0.70) | DPP4DPP8DPP7DPP9ACE | |
| Phosphoric Acid SCHEMBL2570245 | 0.96 | DPP4 (0.70) | DPP4DPP8DPP7DPP9ACE | |
| Phosphoric Acid SCHEMBL2573058 | 0.95 | DPP4 (0.70) | DPP4DPP8DPP7DPP9ACE | |
| Phosphoric Acid SCHEMBL2573060 | 0.95 | DPP4 (0.70) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL14550105 | 0.90 | DPP4 (0.76) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL7891864 | 0.81 | DPP4 (0.67) | DPP4DPP8DPP7DPP9ACE | |
| Sitagliptin SCHEMBL17783 | 0.81 | DPP4 (1.00) | DPP4DPP8DPP7DPP9ACE | |
| Sitagliptin SCHEMBL1289311 | 0.81 | DPP4 (1.00) | DPP4DPP8DPP7DPP9ACE | |
| Sitagliptin SCHEMBL174489 | 0.81 | DPP4 (1.00) | DPP4DPP8DPP7DPP9ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | claimed |
| WO-2011109784-A1 | FORMULATION OF INSULINOTROPIC PEPTIDE CONJUGATES | CONJUCHEM, LLC (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011109787-A1 | METHODS OF ADMINISTERING INSULINOTROPIC PEPTIDES | CONJUCHEM, LLC (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-1951286-A1 | COMBINED USE OF DPP IV INHIBITORS AND GASTRIN COMPOUNDS | Waratah Pharmaceuticals, Inc. (CA) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007041833-A1 | COMBINED USE OF DPP IV INHIBITORS AND GASTRIN COMPOUNDS | WARATAH PHARMACEUTICALS, INC. (CA) | 2007-04-19 | — | — | WO | disclosed |
| EP-1732562-A2 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006083491-A2 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | DPP4 10/4885DPP8 41/4885DPP7 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.